Veyonda® is a novel proprietary formulation of idronoxil, a first-in-class clinical stage candidate being evaluated in combination therapy paired with the Bristol Myers Squibb immunotherapy drug Opdivo® (nivolumab).
It is being evaluated in a phase 1/2 investigator initiated clinical trial for the treatment of solid tumours. Veyonda has shown a good safety profile in previously treated patients. Its immuno-oncology (I-O) properties are being further explored by cancer specialist Professor Paul de Souza. More information can be found on the Clinical Trials page.